Copyright © 2021. Inderes Oyj. All rights reserved.
Käyttäjätili

Hei!

Luo ilmainen tili jotta voit seurata yrityksiä, osallistua foorumin keskusteluun sekä kommentoida meidän sisältöä. Valitse sinulle sopivin tili.

Oliko sinulla jo tili?

Kirjaudu sisään

Carasent: Heading West - Redeye

Muut analyysit 30.03.2021 9:50 Carasent ASA

Redeye increases its estimates and fair value range for Carasent. We argue that the acquisition of Avans Soma was strategically and financially sound, and we expect an accelerated Norwegian expansion, with a Webdoc launch in the neighboring country by H2’21 or early 2022. Carasent merits a premium, as it has >90% recurring revenues in a non-cyclical and steadily growing market, coupled with net retention numbers of 115-120%.

We estimate that Carasent will grow by >70% in 2021 (30% organically), not accounting for
additional acquisitions that probably will be announced later this year. Carasent trades at
EV/Sales 18x on 2021E, which might look pricey in the short-term. However, we argue
that investors have a good chance of earning approximately the growth rate going forward,
as the durability and duration of the profitable growth add cushion in the case of multiple
contraction.

We increase our base case to NOK 55 (40).

Lähde: Finwire News

Carasent ASA is an investment management company that provides services to businesses that develop entrepreneurial and e-health solutions. The company has a system called 'Webdoc' a cloud-based medical record system with integrated add-on services for the private and public health care industry.